89.76
price up icon1.39%   1.13
after-market Handel nachbörslich: 89.76
loading
Schlusskurs vom Vortag:
$88.63
Offen:
$89.065
24-Stunden-Volumen:
2.88M
Relative Volume:
0.47
Marktkapitalisierung:
$110.72B
Einnahmen:
$28.30B
Nettoeinkommen (Verlust:
$126.00M
KGV:
20.63
EPS:
4.35
Netto-Cashflow:
$9.43B
1W Leistung:
-2.44%
1M Leistung:
+4.14%
6M Leistung:
+33.55%
1J Leistung:
+20.32%
1-Tages-Spanne:
Value
$88.07
$89.94
1-Wochen-Bereich:
Value
$86.08
$91.99
52-Wochen-Spanne:
Value
$62.07
$98.90

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Firmenname
Gilead Sciences Inc
Name
Telefon
(650) 574-3000
Name
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Name
Mitarbeiter
18,000
Name
Twitter
@GileadSciences
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
GILD's Discussions on Twitter

Vergleichen Sie GILD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
GILD 89.75 110.72B 28.30B 126.00M 9.43B 4.35
LLY 749.56 703.88B 40.86B 8.37B -2.28B 5.4193
NVO 102.65 467.74B 39.36B 13.79B 9.83B 2.4077
JNJ 155.49 353.35B 87.70B 14.68B 19.03B 13.47
ABBV 171.71 296.46B 55.53B 5.12B 15.62B 3.65
MRK 99.85 248.23B 63.17B 12.15B 14.84B 1.80

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-09-08 Hochstufung BofA Securities Neutral → Buy
2023-09-06 Eingeleitet HSBC Securities Reduce
2023-07-24 Bestätigt Barclays Equal Weight
2023-05-16 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-28 Fortgesetzt Piper Sandler Overweight
2023-01-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Fortgesetzt BofA Securities Neutral
2022-12-09 Herabstufung DZ Bank Buy → Hold
2022-10-31 Hochstufung Barclays Underweight → Equal Weight
2022-10-28 Bestätigt BMO Capital Markets Market Perform
2022-10-28 Bestätigt Cowen Outperform
2022-10-28 Bestätigt JP Morgan Overweight
2022-10-28 Bestätigt Jefferies Buy
2022-10-28 Hochstufung Piper Sandler Neutral → Overweight
2022-10-28 Bestätigt RBC Capital Mkts Outperform
2022-10-28 Hochstufung Truist Hold → Buy
2022-10-28 Bestätigt Wells Fargo Equal Weight
2022-10-04 Hochstufung JP Morgan Neutral → Overweight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-02-28 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-02 Bestätigt BMO Capital Markets Outperform
2022-02-02 Bestätigt BofA Securities Neutral
2022-02-02 Bestätigt RBC Capital Mkts Outperform
2022-02-02 Bestätigt Truist Hold
2022-02-02 Bestätigt Wells Fargo Equal Weight
2022-01-28 Hochstufung Argus Hold → Buy
2022-01-06 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-11-19 Fortgesetzt Piper Sandler Neutral
2021-10-20 Fortgesetzt Cowen Outperform
2021-07-30 Bestätigt BMO Capital Markets Market Perform
2021-07-30 Bestätigt RBC Capital Mkts Outperform
2021-04-01 Hochstufung Bernstein Mkt Perform → Outperform
2021-03-30 Hochstufung Redburn Neutral → Buy
2021-01-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2020-11-03 Fortgesetzt Morgan Stanley Equal-Weight
2020-10-28 Eingeleitet UBS Neutral
2020-09-30 Fortgesetzt Jefferies Buy
2020-09-15 Hochstufung Maxim Group Hold → Buy
2020-07-31 Bestätigt Credit Suisse Neutral
2020-07-31 Bestätigt Morgan Stanley Equal-Weight
2020-07-31 Bestätigt Piper Sandler Overweight
2020-07-31 Bestätigt RBC Capital Mkts Outperform
2020-07-31 Bestätigt SunTrust Hold
2020-07-31 Bestätigt Wells Fargo Equal Weight
2020-07-20 Hochstufung Credit Suisse Underperform → Neutral
2020-06-03 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-05-26 Hochstufung SunTrust Sell → Hold
2020-05-01 Herabstufung JP Morgan Overweight → Neutral
2020-05-01 Herabstufung Raymond James Outperform → Mkt Perform
2020-05-01 Herabstufung SunTrust Hold → Sell
2020-04-27 Herabstufung UBS Buy → Neutral
2020-04-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-04-20 Herabstufung Wells Fargo Overweight → Equal Weight
2020-04-17 Herabstufung CFRA Hold → Sell
Alle ansehen

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

pulisher
03:43 AM

Sjogren’s Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Gilead Sciences, Incyte Corporation, Novartis, GlaxoSmithKline, Janssen Research & Development - Barchart

03:43 AM
pulisher
12:02 PM

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $100.00 - MarketBeat

12:02 PM
pulisher
10:50 AM

Gilead’s GS-6791 ameliorates arthritis symptoms in mice - BioWorld Online

10:50 AM
pulisher
07:09 AM

Intech Investment Management LLC Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

07:09 AM
pulisher
05:12 AM

PNC Financial Services Group Inc. Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

05:12 AM
pulisher
03:59 AM

Gilead Sciences, Inc. (NASDAQ:GILD) Position Increased by Natixis Advisors LLC - MarketBeat

03:59 AM
pulisher
03:31 AM

Latham & Watkins Advises on Gilead Sciences' US$3.5 Billion Senior Unsecured Notes Offering - Legal Desire News Network

03:31 AM
pulisher
Nov 20, 2024

Watkins Advises on Gilead Sciences' US$3.5 Billion Senior Unsecured Notes Offering - Latham & Watkins LLP

Nov 20, 2024
pulisher
Nov 20, 2024

Gilead Sciences (GILD) Announces Issuance of Senior Notes in New Indenture Agreement - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

Gilead Sciences Issues $3.5 Billion in Senior Notes - Investing.com India

Nov 20, 2024
pulisher
Nov 20, 2024

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Nov 20, 2024
pulisher
Nov 20, 2024

Gilead Helps Pen a Children’s Book for Families Facing Breast Cancer - CSRwire.com

Nov 20, 2024
pulisher
Nov 20, 2024

How Gilead Is Driving Global Health Equity And Innovation - Forbes

Nov 20, 2024
pulisher
Nov 20, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by First Horizon Advisors Inc. - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lowered by Ontario Teachers Pension Plan Board - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

B. Metzler seel. Sohn & Co. Holding AG Takes $9.52 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Prospera Financial Services Inc Has $6.59 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 20, 2024
pulisher
Nov 19, 2024

Gilead discloses GS-441524 prodrugs for treatment of viral infections - BioWorld Online

Nov 19, 2024
pulisher
Nov 19, 2024

Ideaya hires Gilead leader to head up commercialization push - FiercePharma

Nov 19, 2024
pulisher
Nov 19, 2024

Parnassus Investments LLC Sells 280,937 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Meeder Asset Management Inc. Purchases 42,444 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Belmont Capital LLC Reduces Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch

Nov 18, 2024
pulisher
Nov 18, 2024

Gilead announces impending layoffs, facility closure - LabPulse

Nov 18, 2024
pulisher
Nov 18, 2024

26 Analysts Assess Gilead Sciences: What You Need To Know - Benzinga

Nov 18, 2024
pulisher
Nov 18, 2024

Royal Bank of Canada Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Amid Seattle downsizing, Gilead cuts 100+ positions at California HQ - FiercePharma

Nov 18, 2024
pulisher
Nov 18, 2024

Gilead’s Livdelzi shows promise in PBC clinical trial - Yahoo Finance

Nov 18, 2024
pulisher
Nov 18, 2024

Gilead Sciences shares target upgraded, holds rating on HIV event outlook - Investing.com India

Nov 18, 2024
pulisher
Nov 18, 2024

5,715 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Aljian Capital Management LLC - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by TrinityPoint Wealth LLC - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Gilead Science to Report Q3 Earnings: What's in the Cards? - MSN

Nov 18, 2024
pulisher
Nov 18, 2024

Empowering women, eliminating viral hepatitis: Gilead’s vision to help drive public health solutions - STAT

Nov 18, 2024
pulisher
Nov 18, 2024

Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis - BioSpace

Nov 18, 2024
pulisher
Nov 17, 2024

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 - GlobeNewswire Inc.

Nov 17, 2024
pulisher
Nov 17, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Swiss National Bank - MarketBeat

Nov 17, 2024
pulisher
Nov 17, 2024

Thrivent Financial for Lutherans Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Nov 17, 2024
pulisher
Nov 17, 2024

14,342 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Atlanta Consulting Group Advisors LLC - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

How Gilead Sciences' HIV & Other Innovations Are Set to Capture Untapped Markets & Drive Massive Growth!Major Drivers - Smartkarma

Nov 16, 2024
pulisher
Nov 16, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Kentucky Retirement Systems - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

CIBC Asset Management Inc Purchases 22,624 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Impax Asset Management Group plc Sells 7,979 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Gilead’s Irish business sees profit slump on falling sales of Covid drug - The Irish Times

Nov 16, 2024
pulisher
Nov 15, 2024

Gilead to see Bay Area layoffs in wake of Seattle office closingSan Francisco Business Times - The Business Journals

Nov 15, 2024
pulisher
Nov 15, 2024

Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch

Nov 15, 2024
pulisher
Nov 15, 2024

Form 424B5 GILEAD SCIENCES, INC. - StreetInsider.com

Nov 15, 2024
pulisher
Nov 15, 2024

Biotech giant Gilead lays off 104 from Bay Area headquarters, including execs - SFGATE

Nov 15, 2024
pulisher
Nov 15, 2024

Cell Therapy Market Poised for Massive Growth (2024-2031) | Gilead Sciences, Inc., Novartis, AG, Vericel Corporation - openPR

Nov 15, 2024
pulisher
Nov 15, 2024

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

Simplify Asset Management Inc. Buys New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Nov 15, 2024

Finanzdaten der Gilead Sciences Inc-Aktie (GILD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Gilead Sciences Inc-Aktie (GILD) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Parsey Merdad
Chief Medical Officer
Nov 06 '24
Option Exercise
57.92
25,000
1,448,000
125,189
Parsey Merdad
Chief Medical Officer
Nov 06 '24
Sale
91.50
25,590
2,341,485
99,599
drug_manufacturers_general BMY
$58.23
price up icon 0.61%
drug_manufacturers_general SNY
$47.98
price up icon 0.42%
drug_manufacturers_general PFE
$25.14
price up icon 0.60%
$289.90
price up icon 0.71%
drug_manufacturers_general NVS
$103.85
price up icon 0.74%
drug_manufacturers_general MRK
$99.85
price up icon 2.76%
Kapitalisierung:     |  Volumen (24h):